aTyr Pharma’s lead drug candidate efzofitimod failed to meet its primary endpoint in a Phase 3 trial for pulmonary sarcoidosis, an inflammatory lung disease. The trial measured reduction in steroid dosage over 48 weeks but showed no statistically significant difference from placebo. Despite the setback triggering an 80% stock price plunge, aTyr plans to engage with the FDA to explore further regulatory paths. The drug’s mechanism targets activated myeloid cells to modulate inflammation without immune suppression.